IFRX has experienced an increase of 18.53% in the premarket. The last trading session closed at $2.590 with a decrease of 0.38%.
What’s happening?
There is no latest news today regarding IFRX. But some of the recent news has been covered down below:
IFRX Announces Positive Data from Second Interim Analysis
IFRX announces positive data from the second interim analysis on 10th August 2021.
The first 10 evaluable patients in the current Phase II open-label research with vilobelimab in Pyoderma Gangraenosum have shown good results (PG).
As previously disclosed, 19 patients were enrolled in the proof-of-concept trial, including 12 in each of the first two dosage groups. Only 10 patients were evaluable for the effectiveness evaluation on day 99 because two of the 12 withdrew from the trial before reaching day 99 of therapy.
After an initial run-in phase with three doses of 800mg on days 1, 4, and 8, patients were treated bimonthly with vilobelimab 800mg, 1600mg, or 2400mg for a total of 26 weeks (until day 189).
Second-quarter 2021 Financial Results
IFRX announced second-quarter 2021 financial results on 5th August 2021. The net financial result for the six months ended June 30, 2021, was €1.0 million, down from €1.1 million for the six months ended June 30, 2020.
This drop is primarily due to greater foreign exchange profits of €2.6 million and higher foreign exchange losses of €2.2 million, as well as a €0.7 million decrease in interest on marketable assets. A €43 thousand gain from a decrease in the allowance for expected credit loss on marketable securities was included in other finance expenditures for the six months ended June 30, 2021.
For the six months ending June 30, 2021, the net loss was €20.9 million, compared to €18.3 million for the same period in 2020.
On June 30, 2021, the Company had approximately €127.5 million in total funds available, consisting of cash and cash equivalents (€72.4 million), current and non-current financial assets (€55.1 million), and other non-current assets (€55.1 million).
Net cash spent in operating operations increased to €18.3 million in the six months ended June 30, 2021, compared to €18.2 million in the six months ended June 30, 2020.
IFRX doses First Patient in Multicenter Phase II Clinical Trial
It was stated on 8th June 2021 that IFRX doses the first patient in multicenter phase II. The first patient in an open-label, multicenter Phase II clinical research assessing vilobelimab alone and in combination with pembrolizumab in patients with PD-1 or PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma has been enrolled (cSCC).
Around 70 individuals are expected to be enrolled in Phase II clinical research, which will take place in Europe, the United States, and other locations. Vilobelimab alone and vilobelimab in conjunction with pembrolizumab will be investigated in this research.
